These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19546835)

  • 21. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
    Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
    Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
    Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
    Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
    Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
    Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
    Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer.
    Tao HQ; He XJ; Ma YY; Wang HJ; Xia YJ; Ye ZY; Zhao ZS
    Hum Pathol; 2011 Oct; 42(10):1401-9. PubMed ID: 21419474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable response after gemcitabine-radiotherapy for invasive pancreatic intraductal papillary mucinous neoplasm: a case report.
    Ochiai T; Igari K; Furuyama T; Ito H; Mitsunori Y; Aihara A; Kumagai Y; Iida M; Odajima H; Tanaka S; Arii S; Yamazaki S
    Int Surg; 2013; 98(4):340-5. PubMed ID: 24229021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Takahashi H; Ohigashi H; Gotoh K; Marubashi S; Yamada T; Murata M; Ioka T; Uehara H; Yano M; Ishikawa O
    Ann Surg; 2013 Dec; 258(6):1040-50. PubMed ID: 23799421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
    Lee SH; Kang CM; Kim H; Hwang HK; Song SY; Seong J; Kim MJ; Lee WJ
    Medicine (Baltimore); 2015 Dec; 94(52):e2168. PubMed ID: 26717359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemoradiation therapy and immunotherapy for pancreatic cancer].
    Egawa S; Motoi F; Fukuyama S; Sunamura M; Unno M
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():258-63. PubMed ID: 16457262
    [No Abstract]   [Full Text] [Related]  

  • 32. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine.
    Endou M; Mizuno M; Nagata T; Tsukada K; Nakahara N; Tsuno T; Osawa H; Kuno T; Fujita M; Hatano M; Yoshida J
    Int J Mol Med; 2005 Feb; 15(2):277-83. PubMed ID: 15647844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
    Lluís F
    Gastroenterol Hepatol; 2009 Feb; 32(2):120-1. PubMed ID: 19231687
    [No Abstract]   [Full Text] [Related]  

  • 35. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
    Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
    Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
    Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
    J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
    Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
    Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
    Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.